Global Pediatric Health (Feb 2024)

Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series

  • Zilac Espitaleta MSc,
  • Alex Domínguez-Vargas PhD,
  • Johanna Villamizar-Martínez MSc,
  • Martha Carrascal-Guzmán MSc,
  • Gustavo Guerrero-Tinoco MSc,
  • Diana Silva-Díaz MSc,
  • Richard Baquero MSc,
  • Claudia Pinto-Bernal MSc,
  • Luz González-Chaparro MSc,
  • Luisa Rojas-Rosas MSc,
  • Pilar Amado-Niño MSc,
  • Mariángel Castillo-Arteaga MSc,
  • Yeferson Alvarez-Gómez MSc,
  • Laura Arguello-Muñoz MSc,
  • William Morales-Camacho MSc,
  • Oscar León-Guerra MSc,
  • Eduardo Egea MSc,
  • Ricardo Galeano-Rodríguez MSc,
  • Ana Quintero-Gómez MSc,
  • Gustavo Aroca-Martínez PhD,
  • Carlos G. Musso PhD

DOI
https://doi.org/10.1177/2333794X241231133
Journal volume & issue
Vol. 11

Abstract

Read online

Objectives. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric cohort to delineate disease presentation and outcomes. Methods. A multicenter cohort of 27 Colombian children with aHUS were included. Patients were grouped by age at onset. Clinical features were compared using analysis of variance (ANOVA) and Fisher exact tests. Renal biopsy was performed on 6 patients who were suspected of having other renal diseases before aHUS diagnosis. Results. Most patients were male (70%). The onset of aHUS occurred frequently before age 4 years (60%) and followed gastroenteritis as the main triggering event (52%). Age groups showed comparable clinical presentation, disease severity, treatment, and outcomes. Pulmonary involvement (67%) was the main extrarenal manifestation, particularly in the 1 to 7 age group ( P = .01). Renal biopsies were as follows: 3 had membranoproliferative glomerulonephritis (MPGN) type I, one MPGN type III, one C3-glomerulonephritis, and one rapidly progressive GN. Genetic screening was available in 6 patients and identified 2x CFHR5 , 2xMCP , 1x ADAMTS13/THBD , and 1x DGKE mutations. A total of 15 relapses were seen, of which 8 (72%) occurred in the 1 to 7 age group. The renal outcome was not significantly different regardless of age group. Conclusion. In our cohort, we observed a relatively high frequency of extrarenal involvement at first presentation represented by pulmonary manifestations. The renal prognosis at initial presentation was worse than in previous reports.